within Pharmacolibrary.Drugs.ATC.C;

model C10AD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AD05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nicotinyl alcohol, also known as pyridylcarbinol, is a vasodilator drug that is structurally related to niacin (nicotinic acid). It was previously used to lower blood lipid levels (hypolipidemic agent) and to improve peripheral circulation, but it is not commonly used or approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models available for nicotinyl alcohol in humans. Estimates based on class similarity (niacin).</p><h4>References</h4><ol><li><p>Cheymol, G, et al., &amp; Poitou, P (1984). [Blood pharmacokinetics of fluorine in man after the oral administration of nicomethanol hydrofluoride]. <i>Journal de biologie buccale</i> 12(4) 349–353. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6597190/\">https://pubmed.ncbi.nlm.nih.gov/6597190</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AD05;
